INTRODUCTION
Breast cancer is the most common malignancy and the second leading cause of cancer-related death after lung cancer among women in the United States and Europe. Due to major advances in screening and early diagnostic procedures, most breast cancer patients are diagnosed at an early stage. However, 6% to 10% of patients still present with metastatic breast cancer at the time of diagnosis; for those patients, relapses tend to occur earlier and survival rates are shortened.
AIMS AND OBJECTIVES
To study MMP 9, Estrogen receptor, Progesterone receptor and Her-2-Neu expression in breast carcinoma by immune histochemistry. Compare MMP 9 expression with result of Estrogen receptor expression, Progesterone receptor expression and Her-2-Neu expression in breast carcinoma. To study MMP 9 expression in relation to staging and grading of breast cancer.
MATERIALS AND METHOD
This cross-sectional study was conducted on a group of patients admitted in Department of General Surgery, R G Kar Medical College & Hospital, Kolkata from January 2018 - Jun 2019. Approval from an institutional review board was obtained at the initiation of the study. All patients were provided with signed informed written consent. Cross sectional, descriptive and observational.
RESULTS AND PUBLICATION
From the above table it is evident that only 2 of the patients with stage II tumor showed MMP9 positivity while 8 were negative, but in case of patients with stage III disease 20 out of 22 showed MMP9 positivity with only 2 of them showing a negative MMP9 pattern. From the above table it is evident that only 1 out of 6 cases with grade 1 breast cancer was positive for MMP9 , while 11 out of 16 cases of grade 2 disease showed MMP9 positivity and all cases with grade 3 was found to be MMP9 positive. The above table clearly shows that out of 12 ER positive breast cancer cases only one third i.e. 4 were MMP9 positive. However, out of 20 ER negative cases 90% i.e. 18 were found to be MMP9 positive.
Utility of Estrogen Receptor, Progesterone Receptor, and HER-2/neuAnalysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma
